Investors

Analysts

Steve Schwartz, CFA
First Analysis
(312) 258-0660
sschwartz@firstanalysis.com

Tracy Marshbanks, Ph.D.
First Analysis
(312) 258-0660
tmarshbanks@firstanalysis.com

Kevin DeGeeter
Director, Equity Research Analyst
Ladenburg Thalmann
(212) 409-2027
KDeGeeter@ladenburg.com

Matthew Tiampo
Senior Research Analyst
Craig-Hallum Capital Group
(612) 334-6356
matt.tiampo@craig-hallum.com

Codexis, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Codexis, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Codexis, Inc. or its management. Codexis, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Print Page Print Page | E-mail Page E-mail Page |

Share Page

X
| Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSIS®

We are an industrial biotechnology company providing unique, state-of-the-art enzyme optmization services and biocatalyst products.


PHARMACEUTICAL ENZYMES

Codexis delivers a range of chemicals at kilogram to multi-ton scale, through a partnered manufacturing network


CODEXIS

WHAT WE DO


Codexis delivers revolutionary biocatalytic routes that no one else can

CODEXIS

MEDIA CENTER


Visit our Media Center for the latest press information, videos, imagery, and technical papers.

CAREERS AT CODEXIS

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information for the investment community


built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue